European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antithrombotic agents - duoplavin is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (asa). duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.for further information please refer to section 5.1.

European Union - English - EMA (European Medicines Agency)

mylan pharmaceuticals limited - acetylsalicylic acid, clopidogrel hydrogen sulfate - acute coronary syndrome; myocardial infarction - antithrombotic agents - clopidogrel/acetylsalicylic acid mylan is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (asa).clopidogrel/acetylsalicylic acid mylan is a fixed-dose combination medicinal product for continuation of therapy in:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionst segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hyprolose; mannitol; carnauba wax; colloidal anhydrous silica; maize starch; microcrystalline cellulose; hydrogenated castor oil; stearic acid; macrogol 6000; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - coplavix is a fixed-dose combination product intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). coplavix is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, coplavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate; aspirin -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - aspirin,clopidogrel hydrogen sulfate -

Australia - English - Department of Health (Therapeutic Goods Administration)

clopidogrel hydrogen sulfate; aspirin; clopidogrel -

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - (acetylsalicylic acid layer) acetylsalicylic acid (as acetylsalicylic acid granulated with starch); (clopidogrel layer) clopidogrel (as clopidogrel hydrogen sulfate form ii) - tablet, film coated - 100 mg - (acetylsalicylic acid layer) acetylsalicylic acid (as acetylsalicylic acid granulated with starch) 100 mg; (clopidogrel layer) clopidogrel (as clopidogrel hydrogen sulfate form ii) 75 mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - clopidogrel hydrogen sulphate; acetylsalicylic acid -